KR970707141A - 종양 괴사 인자-감마(Tumor necrosis factor-gamma) - Google Patents

종양 괴사 인자-감마(Tumor necrosis factor-gamma)

Info

Publication number
KR970707141A
KR970707141A KR1019970702982A KR19970702982A KR970707141A KR 970707141 A KR970707141 A KR 970707141A KR 1019970702982 A KR1019970702982 A KR 1019970702982A KR 19970702982 A KR19970702982 A KR 19970702982A KR 970707141 A KR970707141 A KR 970707141A
Authority
KR
South Korea
Prior art keywords
polypeptide
polynucleotide
gamma
tnf
patient
Prior art date
Application number
KR1019970702982A
Other languages
English (en)
Other versions
KR100507431B1 (ko
Inventor
구오-리앙 유
지안 니
크레이그 에이 로젠
Original Assignee
벤슨 로버트 에이치
휴먼 게놈 사이언시즈, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 벤슨 로버트 에이치, 휴먼 게놈 사이언시즈, 인코포레이티드 filed Critical 벤슨 로버트 에이치
Publication of KR970707141A publication Critical patent/KR970707141A/ko
Application granted granted Critical
Publication of KR100507431B1 publication Critical patent/KR100507431B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 사람 TNF-감마 폴리펩티드 및 상기 폴리펩티드를 암호화하는 DNA(RNA) 및 상기 폴리펩티드를 재조합 기술에 의해 제조하는 방법을 기술한다. 또한 본 발명은 상기 폴리펩티드를, 예를 들어 종양 또는 악성 종양에서의 세포 증식을 억제하는데 사용하고, 감염에 대한 내성을 제공하고, 염증성 활성을 유도하여 상처를 치료하고, 특정 세포 유형의 증식을 자극하여 재발협착증과 같은 질환을 치료하는 방법을 기술한다. 또한 본 발명은 TNF-감마 핵산 서열 내의 변이 또는 TNF-감마 폴리펩티드의 과다발현을 탐지하는 진단 방법을 기술한다. 또한 본 발명은 상기 폴리펩티드에 대한 항체 및 악액질, 패혈증 쇼크, 대뇌의 말라리아, 염증, 관절염 및 이식조직 거부반응을 치료하기 위한 치료제로서의 이의 용도를 기술한다.

Description

종양 괴사 인자-감마(Tumor necrosis factor-gamma)
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (25)

  1. (a) 제1도는 추론된 아미노산 서열을 갖는 폴리펩티드 또는 상기 폴리펩티드의 단편, 유사체 또는 유도체를 암호화하는 폴리뉴클레오티드; 및 (b) ATCC 기탁번호 제75927호 내에 함유된 cDNA에 의해 암호화되는 아미노산 서열을 갖는 폴리펩티드 또는 상기 폴리펩티드의 단편, 유사체 또는 유도체를 암호화하는 폴리뉴클레오티드로 이루어진 그룹으로부터 선택된, 분리된 폴리뉴클레오티드.
  2. 제1항에 있어서, 폴리뉴클레오티드가 DNA인 폴리뉴클레오티드.
  3. 제1항에 있어서, 폴리뉴클레오티드가 RNA인 폴리뉴클레오티드.
  4. 제1항에 있어서, 폴리뉴클레오티드가 게놈 DNA인 폴리뉴클레오티드.
  5. 제2항에 있어서, 폴리뉴클레오티드가 제1도의 추론된 아미노산 서열을 갖는 폴리펩티드를 암호화하는 폴리뉴클레오티드.
  6. 제2항에 있어서, 폴리뉴클레오티드가 ATCC 기탁번호 제75927호의 cDNA에 의해 암호화되는 폴리펩티드를 암호화하는 폴리뉴클레오티드.
  7. 제1항에 있어서, 제1도에 나타낸 바와 같은 폴리펩티드의 암호화 서열을 갖는 폴리뉴클레오티드.
  8. 제2항에 있어서, ATCC 기탁번호 제75927호로서 기탁된 폴리펩티드의 암호화 서열을 갖는 폴리뉴클레오티드.
  9. 제2항에 따른 DNA를 함유하는 벡터.
  10. 제9항에 따른 벡터로 유전적으로 조작된 숙주 세포.
  11. 제10항에 따른 숙주 세포로부터 상기 DNA에 의해 암호화되는 폴리펩티르를 발현시킴을 포함하는 폴리펩티드의 제조 방법.
  12. 제9항에 따른 벡터로 세포를 유전적으로 조작함을 포함하여, 폴리펩티드를 발현가능하게 하는 세포를 제조하는 방법.
  13. 제2항에 따른 DNA로 하이브리드화할 수 있고, TNF-감마 활성을 갖는 폴리펩티드를 암호화하는, 분리된 DNA.
  14. (i) 제1도의 추론된 아미노산 서열을 갖는 폴리펩티드 및 이의 단편, 유사체 및 유도체 및 (ii) ATCC 기탁번호 제75927호의 cDNA에 의해 암호화되는 폴리펩티드 및 상기 폴리펩티드의 단편, 유사체 및 유도체로 이루어진 그룹으로부터 선택된 폴리펩티드.
  15. 제14항에 있어서, 폴리펩티드가 제1도의 추론된 아미노산 서열을 갖는 폴리펩티드.
  16. 제14항에 따른 폴리펩티드에 대한 항체.
  17. 제14항에 따른 폴리펩티드의 작용제.
  18. 제14항에 따른 폴리펩티드에 대한 길항제.
  19. 제14항에 따른 폴리펩티드의 치료학적 유효량을 환자에게 투여함을 포함하여 TNF-감마를 필요로 하는 환자를 치료하는 방법.
  20. 제17항에 따른 작용제의 치료학적 유효량을 환자에게 투여함을 포함하여 TNF-감마를 억제할 필요가 있는 환자를 치료하는 방법.
  21. 제18항에 따른 길항제의 치료학적 유효량을 환자에게 투여함을 포함하여 TNF-감마를 필요로 하는 환자를 치료하는 방법.
  22. 제19항에 있어서, 상기 치료학적 유효량의 폴리펩티드가 생체 내에서 상기 폴리펩티드를 암호화하고 상기 폴리펩티드를 발현시키는 DNA를 환자에게 제공함으로써 투여되는 방법.
  23. 내피 세포, 콘카비린-A, 선별된 화합물, [3H]티미딘을 선택적으로 TNF-감마의 존재 또는 부재하에 합하고 : [3H]티미딘 혼입을 내피 세포에 의해 측정하고; 상기 화합물이 [3H]티미딘 혼입을 증진시키거나 차단하는지의 여부를 측정함을 포함하여, 제14항에 따른 폴리펩티드에 대한 작용제 및 길항제를 동정하는 방법.
  24. 치료학적 유효량의 TNF-감마 단백질을 약제학적으로 허용되는 담체의 임의의 존재하에 환자에게 투여함을 포함하여, 환자의 종양 세포 증식을 억제하는 방법.
  25. 숙주로부터 유도된 샘플 내에서 TNF-감마를 암호화하는 핵산 서열의 변이 형태를 탐지함을 포함하여, 종양 또는 종양에 대한 감수성을 진단하는 방법.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019970702982A 1994-11-07 1994-11-07 종양괴사인자-γ KR100507431B1 (ko)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1994/012880 WO1996014328A1 (en) 1994-11-07 1994-11-07 Tumor necrosis factor-gamma

Publications (2)

Publication Number Publication Date
KR970707141A true KR970707141A (ko) 1997-12-01
KR100507431B1 KR100507431B1 (ko) 2005-12-21

Family

ID=22243251

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019970702982A KR100507431B1 (ko) 1994-11-07 1994-11-07 종양괴사인자-γ

Country Status (9)

Country Link
EP (1) EP0792278B1 (ko)
JP (1) JP4046349B2 (ko)
KR (1) KR100507431B1 (ko)
AT (1) ATE364614T1 (ko)
AU (1) AU708972B2 (ko)
CA (1) CA2203655C (ko)
DE (1) DE69434988T2 (ko)
ES (1) ES2285701T3 (ko)
WO (1) WO1996014328A1 (ko)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824767B2 (en) 1994-11-07 2004-11-30 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US6599719B2 (en) * 1994-11-07 2003-07-29 Human Genome Sciences, Inc. Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha
WO2000066608A1 (en) * 1999-04-30 2000-11-09 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7429646B1 (en) 1995-06-05 2008-09-30 Human Genome Sciences, Inc. Antibodies to human tumor necrosis factor receptor-like 2
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
US6713061B1 (en) 1996-03-12 2004-03-30 Human Genome Sciences, Inc. Death domain containing receptors
WO1997033904A1 (en) 1996-03-12 1997-09-18 Human Genome Sciences, Inc. Death domain containing receptors
US7357927B2 (en) 1996-03-12 2008-04-15 Human Genome Sciences, Inc. Death domain containing receptors
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
US5998171A (en) 1996-08-16 1999-12-07 Human Genome Sciences, Inc. Polynucleotides encoding human endokine alpha
EP0961831B1 (en) * 1996-08-16 2008-10-29 Human Genome Sciences, Inc. Human endokine alpha
US6406867B1 (en) 1996-08-16 2002-06-18 Human Genome Sciences, Inc. Antibody to human endokine alpha and methods of use
US6812327B1 (en) 1996-10-25 2004-11-02 Human Genome Sciences, Inc. Neutrokine-alpha polypeptides
US8212004B2 (en) 1999-03-02 2012-07-03 Human Genome Sciences, Inc. Neutrokine-alpha fusion proteins
EA003636B1 (ru) * 1997-04-16 2003-08-28 Амген Инк. Остеопротегеринсвязующие белки и рецепторы
US6316408B1 (en) 1997-04-16 2001-11-13 Amgen Inc. Methods of use for osetoprotegerin binding protein receptors
US6171787B1 (en) 1997-06-26 2001-01-09 Abbott Laboratories Member of the TNF family useful for treatment and diagnosis of disease
ES2303358T3 (es) * 1997-11-03 2008-08-01 Human Genome Sciences, Inc. Vegi, un inhibidor de la angiogenesis y el crecimiento tumoral.
WO2000050620A2 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6627199B1 (en) 1999-07-09 2003-09-30 Amgen Inc Isolation, identification and characterization of tmst2, a novel member of the TNF-receptor supergene family
AU783682B2 (en) * 1999-08-04 2005-11-24 Amgen, Inc. Fhm, a novel member of the TNF ligand supergene family
AU6517800A (en) 1999-08-04 2001-03-05 Amgen, Inc. Ntr3, a member of the tnf-receptor supergene family
AU2001266557A1 (en) 2000-04-12 2001-10-23 Human Genome Sciences, Inc. Albumin fusion proteins
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
US7879328B2 (en) 2000-06-16 2011-02-01 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator
CA2407910C (en) 2000-06-16 2013-03-12 Steven M. Ruben Antibodies that immunospecifically bind to blys
US20030091565A1 (en) 2000-08-18 2003-05-15 Beltzer James P. Binding polypeptides and methods based thereon
CA2446723C (en) 2001-05-25 2014-01-21 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
AU2002366433A1 (en) 2001-08-16 2003-09-09 Human Genome Sciences, Inc. Methods and compositions for treating metabolic bone diseases relating to human endokine alpha
CN100398551C (zh) 2001-11-09 2008-07-02 乔治敦大学 新的血管内皮细胞生长抑制剂同种型
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
EP1578305A4 (en) 2002-12-10 2008-08-27 Schering Plough Ltd DOG RANKL AND MANUFACTURING AND USE METHOD THEREFOR
WO2005097184A2 (en) 2004-03-26 2005-10-20 Human Genome Sciences, Inc. Antibodies against nogo receptor
EP3037544A1 (en) 2005-10-13 2016-06-29 Human Genome Sciences, Inc. Methods and compositions for use in treatment of systemic lupus erythematosus (sle) patients with autoantibody positive diseases
US9168286B2 (en) 2005-10-13 2015-10-27 Human Genome Sciences, Inc. Methods and compositions for use in treatment of patients with autoantibody positive disease
WO2007123765A2 (en) 2006-03-31 2007-11-01 Human Genome Sciences Inc. Neutrokine-alpha and neutrokine-alpha splice variant
AU2009303690B2 (en) 2008-09-26 2014-06-19 Tocagen Inc. Gene therapy vectors and cytosine deaminases
US20110229471A1 (en) 2008-11-26 2011-09-22 Cedars-Sinai Medical Center Methods of determining responsiveness to anti-tnf alpha therapy in inflammatory bowel disease
SI2403528T1 (sl) 2009-03-02 2016-07-29 Aduro Biotech Holdings, Europe B.V. Protitelesa proti proliferacijo inducirajočemu ligandu (april)
KR101919170B1 (ko) 2010-11-19 2018-11-15 에자이 알앤드디 매니지먼트 가부시키가이샤 중화 항-ccl20 항체
EP2909324B1 (en) 2012-10-25 2020-02-26 Tocagen Inc. Retroviral vector with mini-promoter cassette
CN112870368A (zh) 2013-03-27 2021-06-01 西达-赛奈医疗中心 通过抑制tl1a的功能和相关信号传导途径来减轻并逆转纤维化和炎症
EP3022295A4 (en) 2013-07-19 2017-03-01 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
NL2011406C2 (en) 2013-09-06 2015-03-10 Bionovion Holding B V Method for obtaining april-binding peptides, process for producing the peptides, april-binding peptides obtainable with said method/process and use of the april-binding peptides.
NL2014108B1 (en) 2015-01-09 2016-09-30 Aduro Biotech Holdings Europe B V Altered april binding antibodies.
EP3430172A4 (en) 2016-03-17 2019-08-21 Cedars-Sinai Medical Center METHOD FOR DIAGNOSIS OF INFLAMMATORY ENDURANCE THROUGH RNASET2
CN110121509B (zh) 2016-10-26 2024-05-07 西达-赛奈医疗中心 中和抗tl1a单克隆抗体
US20210070871A1 (en) 2018-04-25 2021-03-11 Prometheus Biosciences, Inc. Optimized anti-tl1a antibodies
KR20220103721A (ko) 2019-10-24 2022-07-22 프로메테우스 바이오사이언시즈, 인크. Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4677063A (en) * 1985-05-02 1987-06-30 Cetus Corporation Human tumor necrosis factor
CA2114311C (en) * 1991-11-25 1996-02-27 Richard Kian-Hock Wee Monoclonal wb b-cell line

Also Published As

Publication number Publication date
WO1996014328A1 (en) 1996-05-17
ES2285701T3 (es) 2007-11-16
DE69434988D1 (de) 2007-07-26
JPH10509030A (ja) 1998-09-08
KR100507431B1 (ko) 2005-12-21
AU708972B2 (en) 1999-08-19
AU1254795A (en) 1996-05-31
EP0792278B1 (en) 2007-06-13
JP4046349B2 (ja) 2008-02-13
EP0792278A1 (en) 1997-09-03
ATE364614T1 (de) 2007-07-15
EP0792278A4 (en) 1999-09-22
CA2203655C (en) 2010-03-23
DE69434988T2 (de) 2008-03-06
CA2203655A1 (en) 1996-05-17

Similar Documents

Publication Publication Date Title
KR970707141A (ko) 종양 괴사 인자-감마(Tumor necrosis factor-gamma)
Graves et al. Identification of monocyte chemotactic activity produced by malignant cells
Nobori et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Schall Biology of the RANTES/SIS cytokine family
EP1146894B1 (en) Uses of thank protein, a tnf homologue, to inhibit growth of tumour cells
AU697535B2 (en) Haemopoietic maturation factor
US5504003A (en) Macrophage inflammatory protein-3 and -4
KR970701776A (ko) 형질전환 성장 인자 알파 에이치1(Transforming growth factor alpha H1)
KR970700438A (ko) 마크로파지 염증성 단백질-3,-4 및 -1감마(MACROPHAGE INFLAMMATORY PROTEINS -3,-4 AND -1sg(g))
KR970705405A (ko) 사람 케모킨 폴리펩타이드(Human Chemokine Polypeptides)
NZ337955A (en) Modified TNF-alpha and their use as vaccines
ATE342967T1 (de) Anti-invasive and anti-angiogene urokinase fragmente und deren verwendung
JPH05503003A (ja) 潜在性関与ペプチドおよびその使用
EP0567575B1 (en) Cytokine-induced protein, tsg-6, dna coding therefor and uses thereof
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
JP2003505075A5 (ko)
SK112996A3 (en) Firoblast growth factor-10
ES2238685T3 (es) Nueva quimioquina expresada en un adenoide inflamado, su produccion y sus utilizaciones.
EP1217067A2 (en) Connective tissue growth factor-2
KR950701379A (ko) neu 수용체의 재조합 자극인자(RECOMBINANT STIMULATING FACTOR OF THE neu RECEPTOR)
KR970705635A (ko) 사람 케모킨 베타-9(Human chemokine beta-9)
RU2004117536A (ru) Новые изоформы ингибитора роста васкулярных эндотелиальных клеток
AU1204301A (en) Novel polypeptides and polynucleotides encoding same
KR970701724A (ko) 스타니어스 단백질인 스타니오칼신의 소체(Corpuscles of stannius protein, stanniocalcin)
EP1466619A2 (en) Method for modulating cell apoptosis

Legal Events

Date Code Title Description
A201 Request for examination
AMND Amendment
E902 Notification of reason for refusal
AMND Amendment
E601 Decision to refuse application
AMND Amendment
J201 Request for trial against refusal decision
B90T Transfer of trial file for re-examination
E902 Notification of reason for refusal
E902 Notification of reason for refusal
B701 Decision to grant
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20120723

Year of fee payment: 8

FPAY Annual fee payment

Payment date: 20130725

Year of fee payment: 9

FPAY Annual fee payment

Payment date: 20140724

Year of fee payment: 10

EXPY Expiration of term